-20℃ 3 years powder
-80℃ 2 years in solvent
Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 3-7 days | 102.00 | |
5 mg | 3-7 days | 167.00 | |
10 mg | 3-7 days | 275.00 | |
50 mg | 3-7 days | 923.00 | |
100 mg | 3-7 days | 1733.00 |
Description | Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist. |
Targets&IC50 | GnRHR, |
In vitro | Degarelix directly acts on the pituitary receptors to luteinizing hormone-releasing hormone (LHRH), preventing the effect of endogenous LHRH. The use of degarelix eliminates the undesirable surge of initial gonadotropin and testosterone levels produced by LHRH agonists. With the exception of PC-3 cells, Degarelix treatment reduces the cell viability of all prostate cell lines (WPE1-NA22, WPMY-1, BPH-1 cells, VCaP cells). GnRH antagonist degarelix has a direct effect on the growth of prostate cells through apoptosis. |
Molecular Weight | 1632.26 |
Formula | C82H103ClN18O16 |
CAS No. | 214766-78-6 |
-20℃ 3 years powder
-80℃ 2 years in solvent
H2O: 25 mg/mL (15.32 mM), Need ultrasonic
DMSO: 10 mg/mL (6.13 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
Safe and effective drug dosing is necessary, regardless of its purpose of administration. Learn More
bottom
Answers to questions you may have can be found in the Inhibitor Handling Instructions. Topics include how to prepare stock solutions, how to store Products, and issues that need special attention for cell-based assays and animal experiments.